$8.25
Insights on Solid Biosciences Inc
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 41.4%
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 319.9%
3.27%
Downside
Day's Volatility :6.88%
Upside
3.73%
78.06%
Downside
52 Weeks Volatility :87.97%
Upside
45.18%
Period | Solid Biosciences Inc | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | -14.86% | 0.0% | 0.0% |
6 Months | 139.83% | 0.0% | 0.0% |
1 Year | 32.0% | 0.0% | 0.0% |
3 Years | -84.81% | -22.6% | -22.6% |
Market Capitalization | 317.0M |
Book Value | $6.2 |
Earnings Per Share (EPS) | -3.93 |
Wall Street Target Price | 16.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -30.67% |
Return On Equity TTM | -56.79% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 13.6M |
EBITDA | -101.7M |
Diluted Eps TTM | -3.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.71 |
EPS Estimate Next Year | -2.69 |
EPS Estimate Current Quarter | -0.64 |
EPS Estimate Next Quarter | -0.64 |
What analysts predicted
Upside of 100.0%
Sell
Neutral
Buy
Solid Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Solid Biosciences Inc | -17.5% | 139.83% | 32.0% | -84.81% | -89.95% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Solid Biosciences Inc | 0.15 | NA | NA | -2.71 | -0.57 | -0.31 | NA | 6.2 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Solid Biosciences Inc | Buy | $317.0M | -89.95% | 0.15 | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Perceptive Advisors LLC
RA Capital Management, LLC
Bain Capital Life Sciences Investors, LLC
Adage Capital Partners Gp LLC
HHG PLC
SILVERARC CAPITAL MANAGEMENT, LLC
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Organization | Solid Biosciences Inc |
Employees | 88 |
CEO | Mr. Ian F. Smith A.C.A., C.P.A. |
Industry | Health Technology |
A Spac I Acquisition Corp
$8.25
-0.12%
Keyarch Acquisition Corp
$8.25
-0.12%
Connexa Sports Technologies Inc
$8.25
-0.12%
Us Value Etf
$8.25
-0.12%
First Wave Biopharma Inc
$8.25
-0.12%
Global X Msci Next Emerging
$8.25
-0.12%
Fat Projects Acquisition Corp
$8.25
-0.12%
Goal Acquisitions Corp
$8.25
-0.12%
Capital Link Global Fintech
$8.25
-0.12%